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Do oxidized lipoproteins contribute to glomerulosclerosis?
Lipoproteins have long been associated with the devel-
opment of atherosclerosis. As atherosclerotic processes
were thought not to occur in capillaries, for a long time
lipids were not considered to be pathogenetic factors in
glomerulosclerosis. Based on early observations of Vir-
chow, Kimmelstiel, Wilson and French, several investiga-
tors have recently gathered experimental evidence in rats
and other small mammals that hyperlipoproteinemia and
hypercholesterolemia can induce and contribute to fibrosis
of glomerular capillaries [reviewed in 1]. Diamond and
Karnovsky coined the term “capillary atherosclerosis” [2].
There are indications that lipid-modulated glomerular
damage also occurs in humans [1]. Patients with lecithin-
cholesterol acyltransferase (LCAT)-deficiency have pro-
nounced dyslipidemia with lipid deposits in glomeruli and
as a consequence develop severe glomerulosclerosis. Apo-
lipoproteins apoB-100 and apoE and LDL-receptor pro-
teins have been detected in glomeruli of patients with
different glomerular diseases [3, 4].
To gain insights into lipoprotein-associated glomerulo-
sclerosis, the effects of usual lipoproteins and lipoproteins
with abnormal composition (such as lipoproteins of pa-
tients with LCAT-deficiency) on mesangial cells and podo-
cytes have been investigated. Native lipoproteins stimu-
lated cell proliferation, the early response genes involved in
DNA synthesis, the synthesis of cytokines/growth factors
(for example, M-CSF, PDGF, MCP-1) and of matrix
proteins such as collagen and fibronectin [1, 5]. As oxida-
tively modified lipoproteins have been strongly implicated
in the genesis of atherosclerosis [6], it was logical to also
analyze the effects of oxidatively modified lipoproteins on
glomerular cells in culture. Oxidatively modified lipopro-
teins exerted the same effects as native lipoproteins when
they were only minimally modified, that is, still able to
specifically bind to the apoB/E receptor. Oxidatively,
greatly modified lipoproteins that bound to scavenger
receptors were antiproliferative and induced apoptosis.
Their effects on the synthesis of growth factors and matrix
proteins have been discussed controversially [7]. Oxida-
tively modified lipoproteins by themselves exert chemotac-
tic effects on granulocytes, T cells and monocytes [8].
In rats with focal segmental sclerosis oxidatively modified
lipoproteins were detected in the glomerular scars [9].
Using immunohistology and Western blot Lee and Kim
in this issue now demonstrate that oxidatively modified
(lipo)proteins can be found in human glomeruli with
immune complex and degenerative diseases often colocal-
izing with apolipoprotein B-100 [10]. The authors have
studied a large number of biopsies to demonstrate oxida-
tively modified lipoproteins in segmental scars and mesan-
gium. Interestingly, oxidatively modified lipoproteins were
not only found in glomerular disease characterized by an
influx of polymorphonuclear leukocytes and monocytes/
macrophages (such as necrotizing glomerulonephritis,
membranoproliferative glomerulonephritis), but also in a
rather high percentage (.25%) of patients with degenera-
tive disease (nephrosclerosis). It is astounding that the
authors could only detect one (kidney tissue) and two
(ox-LDL) modified proteins by Western blot. Oxidative
modification, especially that catalyzed by Cu11 in vitro
usually leads to an irregular fragmentation of apoB-100 and
other fortuitously modified proteins resulting in a smear on
Western blots. The existence of oxidatively modified li-
poproteins did not correlate closely with hypercholesterol-
emia and proteinuria.
This is in contrast to elegant studies in Heymann nephri-
tis, the experimental rat model of human membranous
glomerulopathy. Oxidative modification of the noncollag-
enous domain of collagen type IV in the glomerular
basement membrane, detected with specific antibodies to
malondialdehyde containing epitopes, was correlated with
proteinuria [11]. Also, in these experiments apolipoprotein
E and oxidatively modified epitopes were detected in the
subepithelial immune deposits in the glomerular basement
membrane. Antioxidants significantly decreased protein-
uria [12]. Thus, oxidative modifications within the glomer-
ular basement membrane can cause functional defects.
It is probable that other oxidative products will be found
in human glomeruli and the percentage of glomeruli with
oxidative modifications may well increase significantly in
different glomerular diseases.
Oxidative modifications are generated by a multitude of
chemical reactions resulting in a complex array of different
oxidative epitope modifications [13]. Lee and Kim have
identified malondialdehyde modified epitopes. Evidence
has been provided that oxidative modifications by hypo-
chlorous acid can be found in glomeruli of patients with
nephrosclerosis [14]. Discrete deposits of hypochlorous
acid modified protein were also demonstrated in the base-
ment membrane, in mesangial cells and in podocytes in
human membranous glomerulonephritis [15].
Although Lee and Kim do not specifically address their
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finding of oxidatively modified proteins in basement mem-
branes of regular glomeruli, these results may be relevant
for the understanding of glomerular (re)modeling. Appar-
ently, in normal kidney reactive oxygen species (ROS) and
reactive oxygen compounds are generated in sufficient
quantities to lead to oxidative modifications of glomerular
basement membrane proteins. Alternatively, oxidatively
modified proteins may be filtered into and retained by the
glomerular basement membrane. It is not yet clear whether
these slight oxidative modifications have functional conse-
quences.
Lee and Kim tried in vain to associate the localization of
malondialdehyde modified proteins with the electron-
transporting component of NADPH oxidase. In contrast,
cytochrome b558 mRNA and protein expression has been
found to rise dramatically in podocytes of glomeruli with
Heymann nephritis and with oxidative modification of
glomerular basement membrane structures. Shah and
thereafter many other groups could show that glomeruli,
mesangial cells and visceral epithelial cells can generate
ROS [16]. In hypercholesterolemia isolated rat glomeruli
increase their basal and phorbol myristate acetate stimu-
lated ROS synthesis. Infiltrating monocytes/macrophages
probably participate significantly in this rise of ROS gen-
eration in hyperlipidemia. Monocytes/macrophages are re-
quired for lipid-induced glomerulosclerosis to occur [17].
The new finding by Lee and Kim of only tiny amounts of
NADPH oxidase proteins in glomerular endothelial cells
and podocytes seems to underscore the quintessential role
of monocytes in oxidative processes. Recent studies in the
rat have not only demonstrated an increase in NADH/
NADPH oxidase activity but also in xanthine oxidase
activities in hyperlipidemia (Scheuer H, Gwinner W, Gro¨ne
HJ, manuscript in preparation). It remains still to be
elucidated (1) which enzyme, nonenzymatic pathway or
dysbalance of oxidant/antioxidant enzymes contributes
most to the generation of oxygen species and oxygen
mediated modification, and (2) which mechanisms initiate
these oxidative pathways in hyperlipidemia.
In rat experiments a rise in glomerular ROS was already
found in hypercholesterolemia well before lipid deposits
and oxidatively modified lipoproteins could be localized.
This was also true for tubulointerstitial damage that could
be associated with hyperlipoproteinemia. Oxidatively mod-
ified lipoproteins in glomeruli thus seem to represent
rather late and not obligatory phenomena of lipoprotein-
induced glomerular damage. Nevertheless, these oxidized
proteins may amplify the sclerotic process by their own
inflammatory effects. The overall low percentage of biop-
sies with oxidatively modified lipoproteins may be due to a
rather efficient clearance of oxidation products, and impor-
tantly has to be viewed under the aspect that apparently
weak immunohistologic stains for oxidized protein were not
included in the final evaluation by Lee and Kim.
In summary, the data of the animal and cell culture
experiments and the descriptive data in human biopsies
indeed suggest that oxidatively modified lipoproteins may
contribute to the pathogenesis of glomerulosclerosis. It
seems that the concept for irreversible glomerular damage
has to incorporate lipid-induced oxidative damage and
oxidative modifications of (lipo)proteins as a modulating
factor.
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